Explore the intersection of psychedelic medicine and cultural values, diving into ethical considerations and societal impacts within this transformative field.
Navigate the complex legal and political landscape surrounding psychedelic medicine, including regulatory updates, policy changes, and advocacy efforts.
Delve into cutting-edge scientific research and breakthroughs in the field of psychedelic medicine, with a focus on understanding the mechanisms, efficacy, and safety of these substances.
Delve into the captivating world of psychedelic medicine at Wonderland, where the frontiers of science, spirituality, and wellness converge to create an experience unlike any other.
Discover the keys to living longer while exploring the potential of humanity’s future. Wonderland brings together the latest groundbreaking research, charting trends, and investment opportunities for an experience of a lifetime.
Uncover state-of-the-art technology, evolving trends, insightful marketing strategies, and valuable opportunities designed for professionals in the mental health and brain care sector.
With this year’s Wonderland, we want to expand the conversation to take a deep dive into the intersection of these fields with psychedelic medicine, and how combining all three can lead to living not only a longer, but happier life.
The premier global conference, Wonderland is a groundbreaking event experience where visionaries and pioneers unite to explore the future of psychedelic medicine, the business of mental health and the future of longevity medicine.
Are you ready to share your passion, knowledge, and insights with a global audience of executives, researchers, and practitioners? This is your opportunity to contribute to the evolving conversation on the future of medicine showcase your unique expertise, and inspire change in the world.
Wonderland presents a one-of-a-kind opportunity for businesses and organizations to exhibit their cutting-edge products, services, and visionary solutions to a captivated audience of professionals in the mental health and psychedelic medicine fields.
We invite companies with a shared vision to submit partnership proposals and collaborate with us on this extraordinary event. By joining forces, we can create a truly unique experience for attendees, foster lasting connections, and drive the future of psychedelic healing together.
Elevate your brand’s presence in the psychedelic medicine industry with our comprehensive suite of services, tailored to captivate your audience, strengthen your market position, and foster meaningful connections within the community.
Our advertising options give you the ability to target users on their desktops, mobile devices, or when they’re at one of our in-person events. You decide when and where to connect with our audience.
Our dedicated team provides passion and specialist insight across a variety of sectors and services so, whatever the challenge, the impact is guaranteed.
You’re doing the hard work of changing the world, let our team of internationally award-winning creators focus on spreading the word as far as possible and telling your story to the world.
Microdose’s events and conferences are bringing psychedelic medicine to the mainstream. Top investors, business leaders, researchers, and advocates — our events are the hub for the psychedelic renaissance.
Justin Hanka
MindBio Therapeutics
The team at Microdose are leaders in public relations activities and have successfully assisted MindBio Therapeutics to reach a global audience that we would not have been able to reach without them.
Natalie Dolphin
Wellbeing Digital Science
The Microdose team worked with us, identifying key activities we were undertaking and promoting them through its wide-ranging media connections within psychedelics, cannabis and biotech publications. The Microdose team is professional and passionate about what it does, and this was reinforced during the pandemic when it went above and beyond our agreed contract, working with us to get key messages out to the industry quickly and effectively.
Microdose X is shifting the world’s perception of psychedelic medicine, one city at a time. Join the world’s fastest-growing psychedelic network and enjoy vibrant local meetups with like-minded souls.
The Science of Psychedelics is an accredited, definitive guide to the clinical applications of entheogenic medicines, and offers a solid introduction to psychedelic-assisted therapy and “trip sitting” skills to physicians, psychologists, social workers, mental health counselors, pharmacists, and other empowered individuals. Become trained in psychedelic medicines like psilocybin, LSD, MDMA, and ketamine today.
Psychedelia is a quarterly publication examining the ever-changing realm of drug policy and efforts to bring psychedelic therapies into the mainstream. From psilocybin mushrooms to LSD to DMT, psychedelics have the potential to revolutionize mental healthcare in North America. Psychedelia will detail the journey towards acceptance of psychedelic-assisted therapies.
Microdose is a small team of people who want to help share the potential of psychedelic medicine with the world, bringing together our unique expertise and diverse backgrounds to create a platform that inspires, informs, and fosters a thriving community in this transformative field.
Our team shares a passion for psychedelic medicine and we all have a different story on how we ended up here. We want to share those stories and highlight the amazing people that help us do what we do.
Connect with our team to explore how we can collaborate and unlock the potential of psychedelic medicine together, fostering growth and innovation in this dynamic industry.
NeonMind Files Four Additional Provisional Patents on Psilocybin Preclinical Data
Vancouver, British Columbia–(Newsfile Corp. – March 2, 2021) – NeonMind Biosciences Inc. (CSE: NEON) (OTC Pink: NMBDF) (FSE: 6UF) (“NeonMind“) is pleased to announce that it has filed four new provisional patent applications with the United States Patent and Trademark Office to protect initial data obtained during NeonMind’s preclinical trial.
NeonMind Files Four Additional Provisional Patents on Psilocybin Preclinical Data
To view an enhanced version of this graphic, please visit:
This patent has also been included to support NeonMind’s first filed U.S. provisional patent which has a priority date of December 4, 2019, and has been converted to a Patent Cooperation Treaty (“PCT“) application. By filing one international patent application under the PCT, applicants can simultaneously seek protection for an invention in 152 countries.
“We are encouraged with the preliminary results obtained from our preclinical trial,” says NeonMind President & CEO Robert Tessarolo. “Through an expanded portfolio of patent applications, NeonMind is uniquely positioned to pursue exciting drug development opportunities in the enormously underserved weight management market. There have been so many solutions developed in the past that have disappointed; a new approach is desperately needed. We are actively building out our capabilities to execute the critical phases of drug development needed to support new drug applications to the FDA.”
NeonMind’s patent portfolio has potential rights in 152 countries including the United States. It has filed 10 US provisional patent applications, of which 2 have been converted to PCT applications. The anticipated patent protection expiry of these pending patents is 2041. NeonMind anticipates that its near term activities will support additional applications filed later this year.
Compounds now covered by NeonMind’s pending patents include:
Psilocin, Psilocybin
4-SH-dimethyltryptamine
1-methylpsilocin
4-fluoro-N,N-dimethyltryptamine
O-acetylpsilocin
4-hydroxy-N-methyl-N-isopropyltryptamine
4-hydroxy-N-methyl-N-ethyltryptamine
LSD, LSA, DMT
Treatments that are covered by NeonMind’s pending patents include:
Aiding Weight Loss
Obesity
Compulsive Eating Disorder
Diet Alteration
Reduction of Food Cravings
Decreasing Food Intake
Complications Associated with Obesity
NeonMind owns 100% of all of Its intellectual property except for patents surrounding LSD, LSA and DMT, of which it owns 80%. Translational Life Sciences Inc. a research collaborator, owns the remaining 20%.
About NeonMind Biosciences Inc.
NeonMind has two divisions, a consumer products division with a focus on medicinal mushroom infused products, and a pharmaceutical division engaged in drug development of psychedelic compounds. NeonMind’s consumer division currently sells four NeonMind branded coffee products in Canada through NeonMind’s direct to consumer e-commerce platform. In its pharmaceutical division, NeonMind’s first drug candidate involves psilocybin (a complex organic compound found in psychedelic mushrooms) as a treatment for obesity and related illnesses for which NeonMind is conducting a preclinical trial at the University of British Columbia. NeonMind’s intellectual property includes methods of aiding in weight loss, treating compulsive eating disorder, treating obesity and complications of obesity by administering psilocybin or other psychedelic compounds.
NeonMind’s team includes experts in obesity, psychiatry, psychology, neuroscience, and intellectual property and executives with experience from leading consumer product and pharmaceutical companies. Jeff B. Smith, one of NeonMind’s directors, brings more than 20 years of experience, including executive roles such as Company Group Chairman, at Johnson and Johnson Consumer Companies. Rob Tessarolo, NeonMind’s President and CEO, has 25 years of experience in the pharmaceutical industry and has acted as Chief Executive Officer in several drug development companies, including Cipher Pharmaceuticals Inc. and Mind Medicine (Mindmed) Inc. Trevor Millar, NeonMind’s Chief Psychedelic Officer, was formerly the Chair of MAPS Canada and has extensive experience in the treatment of substance abuse disorder using psychedelic substances.
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or NeonMind’s future performance. The use of any of the words “could”, “expect”, “believe”, “will”, “projected”,”estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on NeonMind’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind’s drug development plans, its ability to retain key personnel, and its expectation as to the development of its intellectual property and other steps in its preclinical and clinical drug development constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.
At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.